Entero Healthcare Solutions Limited has informed the Exchange about Acquisition.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.8 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On September 29, 2025, the board of Entero Healthcare approved two transactions. First, acquiring a 60% stake in Ace Cardiopathy Solutions Private Limited, a Delhi-based wholesale distributor of medical devices, for a cash consideration of INR 59.30–77.10 crore, with completion targeted by January 31, 2026. Ace Cardiopathy reported revenue of about INR 154.8 crore in FY25 (unaudited), INR 176.2 crore in FY24, and INR 153 crore in FY23, and operates in the same line of business as Entero. Second, selling its entire 100% stake in wholly owned subsidiary Suprabhat Pharmaceutical for up to INR 37 lakh to its erstwhile promoters, classified as a related party transaction at arm's length. Suprabhat is a non-core, tiny unit contributing just 0.39% to consolidated income (INR 198.76 million). The Ace Cardiopathy acquisition is not a related party transaction and no specific regulatory approvals are required.
The Ace Cardiopathy acquisition is a strategic bolt-on that strengthens Entero's core medical device distribution business and adds meaningful revenue, with cash deployment of around ₹60–77 crore. The Suprabhat sale is immaterial in size, so the net takeaway for shareholders is incremental, core-business expansion rather than a transformative deal.